198 related articles for article (PubMed ID: 26820170)
21. Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer.
Czarnecka AM; Solarek W; Kornakiewicz A; Szczylik C
Oncol Rep; 2016 Mar; 35(3):1433-42. PubMed ID: 26708631
[TBL] [Abstract][Full Text] [Related]
22. Trk inhibitor GNF‑5837 suppresses the tumor growth, survival and migration of renal cell carcinoma.
Chen Y; Wang H; Chen Y; Wang M; Ding G; Li T
Oncol Rep; 2019 Nov; 42(5):2039-2048. PubMed ID: 31485624
[TBL] [Abstract][Full Text] [Related]
23. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
25. [Anoikis-suppression and invasion induced by tyrosine kinase receptor B in OVCAR3 ovarian cancer cells].
Yu XH; Yang YX; Cai B; Yan Q; He YY; Wan XP
Zhonghua Fu Chan Ke Za Zhi; 2008 Sep; 43(9):695-9. PubMed ID: 19087522
[TBL] [Abstract][Full Text] [Related]
26. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells.
Schempp CM; von Schwarzenberg K; Schreiner L; Kubisch R; Müller R; Wagner E; Vollmar AM
Mol Cancer Ther; 2014 Apr; 13(4):926-37. PubMed ID: 24482380
[TBL] [Abstract][Full Text] [Related]
27. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
28. Tropomyosin-related kinase B promotes distant metastasis of colorectal cancer through protein kinase B-mediated anoikis suppression and correlates with poor prognosis.
Fan M; Sun J; Wang W; Fan J; Wang L; Zhang X; Yang A; Wang W; Zhang R; Li J
Apoptosis; 2014 May; 19(5):860-70. PubMed ID: 24549576
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells.
Dawson H; Grundmann S; Koelzer VH; Galván JA; Kirsch R; Karamitopoulou E; Lugli A; Inderbitzin D; Zlobec I
Histopathology; 2015 Apr; 66(5):715-25. PubMed ID: 25382057
[TBL] [Abstract][Full Text] [Related]
30. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
[TBL] [Abstract][Full Text] [Related]
31. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
32. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.
Eckert LB; Repasky GA; Ulkü AS; McFall A; Zhou H; Sartor CI; Der CJ
Cancer Res; 2004 Jul; 64(13):4585-92. PubMed ID: 15231670
[TBL] [Abstract][Full Text] [Related]
33. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways.
Maeda Y; Kawano Y; Wada Y; Yatsuda J; Motoshima T; Murakami Y; Kikuchi K; Imamura T; Eto M
Oncol Rep; 2015 Apr; 33(4):1844-50. PubMed ID: 25682807
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
Merseburger AS; Simon A; Waalkes S; Kuczyk MA
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1429-34. PubMed ID: 19828003
[TBL] [Abstract][Full Text] [Related]
35. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
Masini C; Sabbatini R; Porta C; Procopio G; Di Lorenzo G; Onofri A; Buti S; Iacovelli R; Invernizzi R; Moscetti L; Aste MG; Pagano M; Grosso F; Lucia Manenti A; Ortega C; Cosmai L; Del Giovane C; Conte PF
BJU Int; 2012 Sep; 110(5):692-8. PubMed ID: 22364110
[TBL] [Abstract][Full Text] [Related]
36. Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.
Zhou J; Luo J; Wu K; Yun EJ; Kapur P; Pong RC; Du Y; Wang B; Authement C; Hernandez E; Yang J; Xiao G; Cha TL; Wu HC; Wu D; Margulis V; Lotan Y; Brugarolas J; He D; Hsieh JT
Oncogene; 2016 Sep; 35(35):4663-74. PubMed ID: 26876207
[TBL] [Abstract][Full Text] [Related]
37. Mitogen-activated protein kinase pathway is pivotal for anoikis resistance in metastatic hepatoma cells.
Cao L; Zhang Z; Han L; Du J; Liang X; Liu Y; Sun W
Mol Med Rep; 2014 Apr; 9(4):1121-7. PubMed ID: 24535322
[TBL] [Abstract][Full Text] [Related]
38. miR-200c targets a NF-κB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer.
Howe EN; Cochrane DR; Cittelly DM; Richer JK
PLoS One; 2012; 7(11):e49987. PubMed ID: 23185507
[TBL] [Abstract][Full Text] [Related]
39. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
40. Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.
Yang Y; Lin H; Zhao L; Song Y; Gao Q
Immunotherapy; 2017 Jun; 9(8):629-635. PubMed ID: 28653574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
